DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20195357

Clinical and surgical outcomes of 3 cycles versus 6 cycles of neoadjuvant chemotherapy in advanced ovarian carcinoma

Monika Thakur, Archana Kumari, S. C. Saha

Abstract


Background: Epithelial cancers are the most common ovarian malignancy accounting for 90% of all type of ovarian cancer. Objective of this study was to evaluate the surgical morbidity and to study clinical outcomes of 3 cycles versus 6 cycles of neoadjuvant chemotherapy.

Methods: A total 30 women with diagnosis of advanced epithelial ovarian cancer were randomly divided equally to receive either 3 cycles (Group 1) or 6 cycles (Group 2) of neoadjuvant chemotherapy. End points noted were duration of surgery, extent of surgery, perioperative complications and length of stay.

Results: Both groups had comparable demographic profile. Surgery was more difficult in early IDS group with lesser percentage of patients achieving minimum intended surgery in early IDS (61.53% versus 80. 47%) peri-operative complications were seen more commonly in early IDS group compared to late IDS group (26.66% versus 69.2%). However mean duration of surgery was similar in both groups. Mean duration of stay in hospital was 5.4 days in late IDS group and 7.6 days in early IDS group. The mean follow-up period in late IDS was 7 months and in early IDS was 5 months. Survival in both groups when patients were followed up till the end of study period (12 months) was similar (p=0.186).

Conclusions: Authors conclude that late IDS may be used as a treatment option in the high-risk group of patients. Though there was no significant difference at 6 months follow up, higher percent of women were disease free in late IDS.


Keywords


Advanced ovarian carcinoma, Epithelial ovarian cancer, Early interval debulking surgery, Late interval debulking surgery, Neoadjuvant chemotherapy

Full Text:

PDF

References


Aletti GD, Eisenhower EL, Santillan A, Axtell A, Aletti A, Chi SD. Identification of patient groups of highest risks from traditional approach to ovarian cancer treatment. Gynecol Oncol. 2011;120:23-8.

Lee SJ, Kim BG, Lee JW. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynecol. 2006;32(1):99-106.

Baekelandt M. The potential role of neoadjuvant chemotherapy in advanced ovarian cancer. Int J Gynecol Cancer. 2003;13:163-8.

Consolidated report of population-based cancer registaries 2001-2004. National cancer registry program. Indian council of medical research. Bangalore: 2006.

Vergote CG, Trope F, Amant GB. EORTC-GCG/NCIC-CTG randomized trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage III C -IV ovarian, fallopian tube and peritoneal cancer. Plenary presentation at the 12th Biennial meeting. International Gynecologic Cancer Society IGCS, Bangkok, Thailand October; 2008(abs.); 2008:25-28.

Stoeckle E, Boubli B, Floquet A, Brouste V, Sire M, Croce S, et al. Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined? Eu J Obstet Gynecol Repro Biol. 2011;159:407-12.

Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi DA, Santi AD, et al. Neoadjuvant chemotherapy is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO stage IIIc and IV). J Surg Oncol. 2013;107:195-200.

Deo SV, Goyal H, Shukla NK. Neoadjuvant chemotherapy followed by surgical cytoreduction in advanced epithelial ovarian cancer. Indian J Cancer. 2006;43(3):117-21.

Pajtler M, Cugalj B, Milojković M, Makarović Z. The importance of directed cytological examinations in the diagnosis of ovarian tumors. Jugosl Ginekol Perinatol. 1989;29(3-4):133-6.

Sood T, Handa U, Mohan H, Goel P. Evaluation of aspiration cytology of ovarian masses with histopathological correlation. Cytopathol. 2010;21(3):176-85.

Geir G, Kraus H, Schuhman R. Aspiration biopsy in ovarian tumors. Geburtshilfe Frauenheilked. 1975;35(1):48-54.

Cefis F, Forni A, Carinelli S. Significance of acsitic fluid and peritoneal washing in ovarian tumor diagnosis. Tumori. 1978;64(1):77-8.

Goff BA, Mandel LS, Muntz HG, Melancon CH. Ovarian cancer diagnosis: results of a national ovarian cancer survey. Cancer. 2000;89:2068-75.